Product Description
an oral, non-systemic approach to weight loss
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Gelesis
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NCT04257123 | N/A |
Completed |
Weight Loss|Obesity|Overweight |
2020-11-30 |
2022-04-22 |
Primary Endpoints |
|
| GLOW-EX | N/A |
Completed |
Overweight|Obesity |
2017-12-08 |
2020-10-24 |
||
| G-04 | N/A |
Completed |
Obesity|Overweight |
2017-06-01 |
2020-10-24 |
Primary Endpoints |
|
| GS-100-006 | N/A |
Completed |
Obesity|Overweight |
2016-07-01 |
2019-03-20 |
Treatments |
|
| GS-100-005 | N/A |
Completed |
Overweight |
2015-12-01 |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/01/2022 |
PubMed |
AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. |
|
09/01/2021 |
PubMed |
Oral Superabsorbent Hydrogel (Plenity) for Weight Management. |
|
09/04/2020 |
News Article |
Plenity® Efficacy and Safety Data to be Presented at the European and International Congress on Obesity 2020 |
|
11/05/2019 |
News Article |
Pivotal Data Presented at ObesityWeek 2019 Highlight the Therapeutic Benefits of PlenityTM in Adults with Obesity and Underscore its Safety and Efficacy in Lower-BMI Overweight Adults |
|
10/29/2019 |
News Article |
New Plenity™ Pivotal Safety and Efficacy Data to be Presented at ObesityWeek 2019 |
|
06/25/2019 |
News Article |
Hercules Capital Announces Multiple Portfolio Company Achievements in Q2 2019 |